✦ LIBER ✦

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors

✍ Scribed by Marcé, Silvia; Zamora, Lurdes; Cabezón, Marta; Xicoy, Blanca; Boqué, Concha; Fernández, Cristalina; Grau, Javier; Navarro, José-Tomás; Fernández de Sevilla, Alberto; Ribera, Josep-Maria; Feliu, Evarist; Millá, Fuensanta

Book ID: 122780237
Publisher: Elsevier Science
Year: 2013
Tongue: Spanish
Weight: 267 KB
Volume: 141
Category: Article
ISSN: 0025-7753
DOI: 10.1016/j.medcli.2012.10.028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multiple BCR-ABL kinase domain mutations

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

✍ Neil P. Shah; John M. Nicoll; Bhushan Nagar; Mercedes E. Gorre; Ronald L. Paquet 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 275 KB

The Achievement of a 3-Month Complete Cy

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

✍ Jabbour, Elias; Kantarjian, Hagop; Ghanem, Hady; O'Brien, Susan; Quintas-Cardama 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 305 KB

Molecular responses at 3 and 6 months af

Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib

✍ Boquimpani, Carla; Schaffel, Rony; Biasoli, Irene; Bendit, Israel; Spector, Nels 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 715 KB

Choosing the best treatment strategy for

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

✍ Jabbour, E; Hochhaus, A; Cortes, J; La Rosée, P; Kantarjian, H M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 326 KB

Drug resistance and BCR-ABL kinase domai

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr

✍ Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina; Paolini, Stef 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

Several types of mutations of the Abl ge

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

✍ Roche-Lestienne, C. 📂 Article 📅 2002 🏛 American Society of Hematology 🌐 English ⚖ 270 KB